12,372 trials
Cytokine Storm (Covid-19)
Primary: Proportion of Patients Who Die, Develop Respiratory Failure [Require Mechanical Ventilation] or Require Intensive Care Unit (ICU) Care — 34; 17 Participants — p=0.769
ADHD
Primary: Efficacy of SPN-812 Assessed by Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale, 5th Edition (ADHD-RS-5) — -10.9; -16.6; -17.7 score on a scale — p=0.0004
Triple-negative Breast Cancer
Primary: Number of Participants With Pathologic Complete Response (pCR) Using American Joint Committee on Cancer (AJCC) Staging System in ITT Population — 69; 95 Number of…
Pulmonary Infections · Pseudomonas Aeruginosa
Primary: Number of Participants With Adverse Events (AEs) — 23 Participants
Carcinoma, Hepatocellular
Primary: Overall Survival (OS) — 10.1; 8.9; 9.1; 9.0 months — p=>0.991
Postoperative Pain · Abdominal Surgery
Primary: Mean Pain Intensity on Movement — 4.9; 5.0; 2.8; 3.9 score on a scale — p=0.1473
Post Operative Surgical Site Infection
Primary: Number of Clinically Significant Deep Surgical Site Infection (SSI) — 29; 48; 1; 1 surgical site infections
Locally Recurrent Breast Cancer · Metastatic Breast Cancer
Primary: Kaplan-Meier Estimate of Overall Survival: Intention to Treat (ITT) Population — 12.4; 10.3 Months — p== 0.0835
Controlled Ovarian Simulation
Primary: Ongoing Pregnancy Rate — 31.3; 25.7 percentage of participants
Acute Otitis Externa
Primary: Number of Participants With Clinical Cure of AOE — 190; 191 Participants
Smallpox
Primary: Vaccinia-Specific Neutralizing Antibodies Measured by Plaque Reduction Neutralization Test (PRNT) — 252.7; 269.9; 242.0 Titer
CCND1 Gene Amplification · CCND2 Gene Amplification · CCND3 Gene Amplification
Primary: Objective Response Rate (Confirmed and Unconfirmed, Complete and Partial) — 6 percentage of participants
Topical Antisepsis
Primary: log10 Reductions From Baseline for Each Test Parameter in CFU (Colony Forming Unit)/cm2 on Inguinal and Abdominal Sites — 3.51; 3.44; 3.15; 0.92 Average log10 reductions…
Parathyroid Carcinoma · Primary Hyperparathyroidism
Primary: The Number and Percentage of Patients Who Achived a Serum Corrected Ca Concentration of Under 10.3 mg/dL for at Least 2weeks During Titration Phase. — 14 Participants
FGFR1 Gene Amplification · FGFR1 Gene Mutation · FGFR2 Gene Amplification
Primary: Objective Response Rate (Confirmed and Unconfirmed, Complete and Partial) — 7 percentage of participants